Telementoring Intervention (ECHO) for the Transformation of Professional Engagement, Practice Efficiency, and Community Building Through Team Meetings in Diagnostic Imaging Clinicians

NCT ID: NCT04196972

Last Updated: 2025-10-27

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

NA

Total Enrollment

36 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-08-16

Study Completion Date

2026-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This trial studies how well the Extension for Community Healthcare Outcomes (ECHO) telementoring intervention works in transforming professional engagement, practice efficiency, and community building through team meetings in diagnostic imaging clinicians. This study may help researchers learn more about the potential benefits of a model for team meetings aimed at bringing physicians together from multiple practice locations when few opportunities exist for meaningful, collegial interactions. It may also help diagnostic imaging clinicians engage more effectively with colleagues at distant sites and become more engaged with their work.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

PRIMARY OBJECTIVE:

I. To determine the feasibility of the proposed anti-burnout intervention for faculty at MD Anderson, defined as at least 35/50 of participants each attending at least 9 out of 13 sessions.

SECONDARY OBJECTIVES:

I. To explore any changes in burnout, measured by the Maslach Burnout Inventory (MBI) and Mini-Z surveys.

II. To explore any changes in the self-reported health status of participants, as measured by the RAND Short-Form 36 (SF36) survey.

III. To understand participants' perception of the benefits and usefulness of the intervention, measured by the customized Globalized Perception/Impression of Benefits Survey.

IV. To define methods for improving the intervention, based on participants' feedback following each session.

OUTLINE: Participants are randomized to 1 of 2 arms.

ARM A: Participants attend ECHO telementoring sessions over 1 hour weekly for 13 weeks.

ARM B: Participants are placed on a wait-list for 13 weeks and then attend ECHO telementoring sessions over 1 hour weekly for 13 weeks.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hematopoietic and Lymphoid Cell Neoplasm Malignant Solid Neoplasm

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SEQUENTIAL

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Arm A (ECHO telementoring)

Participants attend ECHO telementoring sessions over 1 hour weekly for 13 weeks.

Group Type EXPERIMENTAL

Communication Intervention

Intervention Type OTHER

Receive ECHO telementoring intervention

Questionnaire Administration

Intervention Type OTHER

Ancillary studies

Arm B (wait-list, ECHO telementoring)

Participants are placed on a wait-list for 13 weeks and then attend ECHO telementoring sessions over 1 hour weekly for 13 weeks.

Group Type EXPERIMENTAL

Communication Intervention

Intervention Type OTHER

Receive ECHO telementoring intervention

Questionnaire Administration

Intervention Type OTHER

Ancillary studies

Waiting List

Intervention Type OTHER

Placed on wait-list

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Communication Intervention

Receive ECHO telementoring intervention

Intervention Type OTHER

Questionnaire Administration

Ancillary studies

Intervention Type OTHER

Waiting List

Placed on wait-list

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Waitlist

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Faculty must be diagnostic imaging clinicians with a primary appointment in the Division of Diagnostic Imaging at MD Anderson

Exclusion Criteria

* Faculty that have an official leadership role (Division Head or Department Chair)
* Faculty that have previously participated in any previous live ECHO clinic or ECHO activity
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Cancer Institute (NCI)

NIH

Sponsor Role collaborator

M.D. Anderson Cancer Center

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Eduardo Bruera

Role: PRINCIPAL_INVESTIGATOR

M.D. Anderson Cancer Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

M D Anderson Cancer Center

Houston, Texas, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Related Links

Access external resources that provide additional context or updates about the study.

http://www.mdanderson.org

M D Anderson Cancer Center

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NCI-2019-07565

Identifier Type: REGISTRY

Identifier Source: secondary_id

2019-0639

Identifier Type: OTHER

Identifier Source: secondary_id

2019-0639

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

RCT of QPS vs General Information Sheet
NCT03287492 ACTIVE_NOT_RECRUITING NA